Oxaliplatin-Induced Neuropathy Management

Introduction to Neuropathy Management

The American Society of Clinical Oncology recommends that oxaliplatin dose should be reduced or discontinued when patients develop grade 2 persistent neuropathy or any grade 3 neuropathy that interferes with function 1

For Grade 2 persistent (>7 days) neuropathy, the National Comprehensive Cancer Network recommends reducing oxaliplatin dose to 65 mg/m² 1
For functional impairment, the American Society of Clinical Oncology suggests assessing the appropriateness of stopping chemotherapy if a patient develops intolerable neuropathy that affects daily activities 1
For persistent Grade 3 neuropathy, the National Comprehensive Cancer Network recommends permanently discontinuing oxaliplatin 1

Consider a "stop-and-go" approach (OPTIMOX strategy) where oxaliplatin is discontinued after 3-4 months of therapy (or sooner if significant neurotoxicity develops ≥grade 2) 2
Oxaliplatin may be reintroduced if it was discontinued for neurotoxicity rather than disease progression 2

For low-risk patients (T1-3, N1), the American Society of Clinical Oncology suggests considering shorter duration (3 months) of oxaliplatin-containing therapy to reduce neurotoxicity risk 4
For high-risk patients (T4 and/or N2), the American Society of Clinical Oncology recommends a standard 6-month duration despite higher neurotoxicity risk 4

Calcium/magnesium infusions are no longer recommended as they have not been shown to reduce oxaliplatin-induced neurotoxicity 3